Up-regulation of Id1 in peripheral blood of psoriatic patients

C. Ronpirin¹, M. Achariyakul², T. Tencomnao³, J. Wongpiyabovorn⁴,⁵ and W. Chaicumpa⁶

¹Department of Preclinical Science, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
²Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
³Department of Clinical Chemistry, Faculty of Allied Health Sciences, Center for Excellence in Omics-Nano Medical Technology Project Development, Chulalongkorn University, Bangkok, Thailand
⁴Department of Microbiology, Immunology Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
⁵Lupus Research Unit, Chulalongkorn University, Bangkok, Thailand
⁶Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Corresponding author: C. Ronpirin
E-mail: cronpirin@yahoo.com

Received June 29, 2010
Accepted August 8, 2010
Published November 16, 2010
DOI 10.4238/vol9-4gmr963

ABSTRACT. Although the precise causes of psoriasis are unclear, it is widely accepted that psoriasis is a disorder in which factors in the immune system, enzymes, and other biochemical substances that regulate skin cell division are impaired, leading to rapid proliferation of keratinocytes and incomplete keratinization. Expression of the helix-loop-helix transcription factor Id1 (inhibitor of differentiation/DNA binding), functioning as an inhibitor of differentiation, is known to increase in psoriatic skin. However, the molecular involvement of this particular biomarker in the psoriatic immune system remains to be elucidated. We measured Id1 mRNA expression in peripheral blood mononuclear cells (PBMCs) of psoriatic patients and healthy controls using semi-quantitative reverse transcriptase-
PCR. The normalized level of Id1 transcripts in psoriatic patients was about 2-fold higher than that in controls (P < 0.05). When we examined the proliferation rate of PBMCs, the stimulation index obtained from the phytohemagglutinin stimulation assay was not significantly different in psoriatic patients. In patients with psoriasis, there was no correlation between the stimulation index and the psoriasis area severity index. We suggest that Id1 has a role in causing psoriatic immune cell symptoms.

Key words: PBMCs; Psoriasis; Gene expression analysis; Proliferation; Id1; mRNA

INTRODUCTION

Psoriasis, affecting approximately 2-4% of the population worldwide, is a common immunologically mediated inflammatory and hyperproliferative disease of the skin and joints, with a multifactorial genetic basis (Henseler, 1998; Ronpirin and Tencomnao, 2010). In histopathology, mixed inflammatory infiltrates are observed, primarily consisting of lymphocytes and monocytes (Ackerman, 1978). In recent years, it has been revealed that psoriatic skin lesions respond to certain immunosuppressive agents such as methotrexate, cyclosporine and macrolide immunosuppressants (Jeffes et al., 1995; Ozawa et al., 1999; Marsland and Griffiths, 2002). Another frequently used treatment modality in psoriasis, referred to as phototherapy, targets principally immune cells located in the epidermis and dermis (Vallat et al., 1994). The role of activated lymphocytes and monocytes in the immunopathogenesis of psoriasis is now broadly acknowledged. Furthermore, it has been shown that lymphocyte activation in the peripheral blood plays a central part in the pathogenesis of psoriasis (Abrams et al., 2000). Taken together, psoriasis is regarded as a type 1 T cell (Th1)-associated disease, since alterations in cytokine production both locally and systemically have been demonstrated (Schön and Boehncke, 2005; Lowes et al., 2007). As a result, systematically administered anti-lymphocyte and anti-tumor necrosis factor alpha (TNF-α) antibodies have been proven to provide impressive improvement of psoriasis (Krueger et al., 2000; Gottlieb et al., 1995, 2000, 2003; Kupper, 2003).

Because there is no known mechanism or disease process to explain psoriasis, several research groups have examined various genes as molecular markers responsible for the pathogenesis of psoriasis. The helix-loop-helix transcription factor Id1 (inhibitor of differentiation or inhibitor of DNA binding) has recently received much attention. It is a transcription factor that suppresses cell differentiation, but promotes cell proliferation and survival. Its expression was found in several cell types such as synovial tissues of patients with rheumatoid arthritis and tumor cells (Sakurai et al., 2001; Wong et al., 2004). Very interestingly, elevated Id1 gene expression was reported in keratinocytes of psoriatic patients’ skin (Bjorntorp et al., 2003), and an activated Id1 pathway was subsequently corroborated by another investigation (Mark et al., 2006), suggesting its molecular role in psoriasis.

However, Id1 expression status in psoriatic immune system, particularly peripheral blood lymphocytes and monocytes, has never been elucidated. In the present study, our objectives were to examine the expression of Id1 mRNA transcripts in peripheral blood mononuclear cells (PBMCs) of psoriatic patients, compared to healthy controls, and to investigate the role of Id1 expression with respect to proliferation of PBMCs as well as the correlation between severity of psoriasis and proliferation of PBMCs.
Up-regulation of Id1 in peripheral blood of psoriatic patients

MATERIAL AND METHODS

Blood samples

Participants in the present study consisted of 15 Thai patients with psoriasis (mean age ± SD = 56.133 ± 13.93 years) diagnosed clinically by an experienced dermatologist at Thammasat Chalermprakiat Hospital and 9 unrelated healthy Thai volunteers (35.56 ± 8.88 years) without a family history of psoriasis, recruited from the Faculty of Medicine, Thammasat University and the Faculty of Allied Health Sciences, Chulalongkorn University. All patients were free from any systemic skin therapies and/or phototherapy. The severity of psoriasis was classified according to European Medicines Agency Committee by the psoriasis area and severity index (PASI): <10 = mild, 10-20 = moderate, >20 = severe (Naldi, 2010). The Ethics Committee of Medical Experiments on Human Subjects (Faculty of Medicine, Thammasat University) approved the study. Informed consent was obtained from all participants prior to inclusion in the study.

Isolation of PBMCs

PBMCs were isolated from 10 mL blood from each subject using standard Ficoll density gradient centrifugation. Subsequently, lymphocytes were subjected to further experiments: analysis of Id1 mRNA expression and lymphocyte proliferation assay.

Total RNA extraction and semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR)

Total cellular RNA was isolated from lymphocytes using Trizol reagent (Invitrogen, Carlsbad, CA, USA), according to manufacturer instructions. The amount of RNA was determined by absorbance at 260 nm. First-strand cDNA was synthesized from 200 ng DNase I-treated RNA using the ImProm-II Reverse Transcription System (Promega, Madison, WI, USA) with oligo(dT)17 primer, following the manufacturer protocol. RT was carried out at 42°C for 60 min. After cDNA synthesis, the desired DNA fragment was then amplified for 35 cycles using MasterTaq (Eppendorf, Hamburg, Germany) with specific primers for Id1 transcripts [sense primer: 5’-TTC AGC CAG TCG CCA AGA ATC-3’ and anti-sense primer: 5’-GCG CTG ATC TCG CCG TTG AG-3’] (Ishiguro et al., 1996) and for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) internal control transcripts [sense primer: 5’-GAA GGT GAA GGT CGG AGT C-3’ and anti-sense primer: 5’-GAA GAT GGT GAT GGG ATT TC-3’] (Hu et al., 2004). Each cycle of PCR consisted of a 30-s denaturation at 94°C, a 1-min annealing at 60°C for Id1 or 58°C for GAPDH, and a 1-min extension at 72°C. The products of RT-PCR were resolved by 1.5% agarose gel electrophoresis and visualized by ethidium bromide staining. The DNA bands corresponding to Id1 and GAPDH transcripts were 434 and 226 bp, respectively. All band densities were analyzed by the 1D-Multi Lane Densitometry program in an AlphaImager 2000 (Alpha Innotech Corp., San Leandro, CA, USA). The Id1 density was normalized to GAPDH density.

Cell proliferation assay

PBMCs prepared from patients with psoriasis and healthy controls were evaluated for their proliferation rate using 3H-thymidine uptake. Briefly, cells were stimulated with 5 µg/mL phytohemagglutinin (PHA) for 72 h at 37°C in 5% CO2. They were pulsed with 1 µCi/mL 3H-methyl-thymi-
dine (\(^3\)H-TdR) during the last 6 h of incubation. After incubation, cells were harvested and \(^3\)H-TdR incorporation was measured using a scintillation counter (Packard Instruments, Downers Grove, IL, USA). The stimulation index (SI) was calculated as the ratio between counts per min obtained in the presence of PHA and that obtained without PHA. A positive response was considered as a difference between PHA-treated cells and untreated cells greater than 2000 and an SI greater than 5.

**Statistical analysis**

Each experiment was performed in triplicate. The data represented the mean ± SD of three independent experiments and were analyzed by the Student t-test. The correlation coefficient was calculated using Pearson’s correlation. Differences at P < 0.05 were considered to be significant.

**RESULTS**

Using semi-quantitative RT-PCR, expression of Id1 mRNA transcripts was found in both patients with psoriasis (N = 7) and healthy controls (N = 5) as shown in Figure 1A. Our semi-quantitative analysis demonstrated that Id1 mRNA expression in the psoriatic samples was approximately 2-fold higher than in the control samples with regard to the normalized Id1 mRNA expression (Figure 1B). The difference in Id1 mRNA expression between the two groups was statistically significant (P < 0.05).

**Figure 1.** Expression of Id1 mRNA as detected by semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) in PBMCs isolated from normal controls and patients with psoriasis. **A.** 1.5% agarose gel electrophoresis (P; lanes 1-7) and normal controls (N; lanes 8-12). **B.** Box plot showing normalized Id1 mRNA expression, comparing the two groups. Id1 = inhibitor of differentiation or inhibitor of DNA binding; GAPDH = glyceraldehyde-3-phosphate dehydrogenase.
Up-regulation of Id1 in peripheral blood of psoriatic patients

Using ³H-thymidine uptake, PBMCs prepared from normal controls (N = 9) and patients with psoriasis (N = 15) were analyzed for their proliferation rate. All PBMCs of controls had a positive response as clearly shown by SI, whereas one patient with psoriasis had a negative response (SI = 2). Nonetheless, no difference between the two groups was found with respect to the proliferation of PBMCs (P > 0.05) as demonstrated in Figure 2.

![Box plot showing stimulation index (SI) as proliferation of PBMCs isolated from normal controls and patients with psoriasis, determined by ³H-thymidine uptake.](image)

Figure 2. Box plot showing stimulation index (SI) as proliferation of PBMCs isolated from normal controls and patients with psoriasis, determined by ³H-thymidine uptake.

We were able to determine the correlation between PASI score and SI with respect to patients with psoriasis (N = 15), since patient characteristics with clinical data recorded at the time of enrollment and resulting experimental data were available with regard to each patient, which were put together as shown in Table 1. Using Pearson’s correlation as an analytical tool, no correlation between PASI score and SI was found (P > 0.05), as depicted in Figure 3.

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Gender</th>
<th>Age (years)</th>
<th>Age at onset of symptoms (years)</th>
<th>Most recent psoriatic lesions observed prior to enrollment (months)</th>
<th>Stimulation index (SI)</th>
<th>PASI score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Female</td>
<td>65</td>
<td>24</td>
<td>12</td>
<td>74</td>
<td>3.4</td>
</tr>
<tr>
<td>2</td>
<td>Male</td>
<td>25</td>
<td>14</td>
<td>1</td>
<td>35</td>
<td>1.9</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>72</td>
<td>71</td>
<td>2</td>
<td>2</td>
<td>1.6</td>
</tr>
<tr>
<td>4</td>
<td>Female</td>
<td>53</td>
<td>48</td>
<td>3</td>
<td>43</td>
<td>1.8</td>
</tr>
<tr>
<td>5</td>
<td>Female</td>
<td>47</td>
<td>30</td>
<td>12</td>
<td>94</td>
<td>5.9</td>
</tr>
<tr>
<td>6</td>
<td>Female</td>
<td>53</td>
<td>34</td>
<td>24</td>
<td>83</td>
<td>4.5</td>
</tr>
<tr>
<td>7</td>
<td>Female</td>
<td>58</td>
<td>20</td>
<td>60</td>
<td>52</td>
<td>11.9</td>
</tr>
<tr>
<td>8</td>
<td>Female</td>
<td>63</td>
<td>58</td>
<td>24</td>
<td>38</td>
<td>1.8</td>
</tr>
<tr>
<td>9</td>
<td>Male</td>
<td>68</td>
<td>66</td>
<td>1</td>
<td>13</td>
<td>6.6</td>
</tr>
<tr>
<td>10</td>
<td>Male</td>
<td>75</td>
<td>70</td>
<td>6</td>
<td>20</td>
<td>2.3</td>
</tr>
<tr>
<td>11</td>
<td>Female</td>
<td>58</td>
<td>39</td>
<td>2</td>
<td>37</td>
<td>4.3</td>
</tr>
<tr>
<td>12</td>
<td>Female</td>
<td>37</td>
<td>31</td>
<td>12</td>
<td>37</td>
<td>0.3</td>
</tr>
<tr>
<td>13</td>
<td>Male</td>
<td>69</td>
<td>36</td>
<td>12</td>
<td>23</td>
<td>2.2</td>
</tr>
<tr>
<td>14</td>
<td>Male</td>
<td>41</td>
<td>25</td>
<td>12</td>
<td>14</td>
<td>5.2</td>
</tr>
<tr>
<td>15</td>
<td>Male</td>
<td>58</td>
<td>35</td>
<td>12</td>
<td>15</td>
<td>1.2</td>
</tr>
</tbody>
</table>

PASI = psoriasis area and severity index.

Table 1. Patient characteristics with clinical and experimental data for the study population.
DISCUSSION

Patients enrolled in this study were mainly classified as having mild psoriasis since their PASI scores were less than 10. There was only one patient with moderate psoriasis (PASI = 11.9). Nevertheless, for the first time, about 2-fold higher expression of Id1 mRNA transcripts in PBMCs was found in the patient group compared to the control group (P < 0.05), as detected by semi-quantitative RT-PCR. Our finding was in agreement with the previously reported up-regulation of Id1 mRNA transcripts in keratinocytes of psoriatic involved skin as compared to uninvolved skin from the same patients and to skin from normal controls (Bjorntorp et al., 2003; Mark et al., 2006).

As far as human cells are concerned, it has been demonstrated that Id genes are expressed in human acute myelogenous leukemia cells, and that knockdown of Id1 expression inhibits leukemic cell growth in vitro, suggesting that Id1 is required for leukemic cell proliferation (Suh et al., 2008). Id1 has been shown to be a common downstream target of tyrosine kinases in leukemic cells, thus making it a potential therapeutic target for leukemias (Tam et al., 2008). Regarding a signaling cascade, it should be noted that the induction of protein tyrosine kinases is known to be a key element in the activation of lymphocytes. In particular, tyrosine phosphorylation in psoriatic T cells has been demonstrated to be modulated by drugs that induce or improve psoriasis (Ockenfels et al., 1995). Therefore, our present finding, up-regulation of Id1 gene expression in psoriatic PBMCs, may also be due to a molecular

![Pearson's correlation between psoriasis area and severity index (PASI) score (y represents linear regression equation; R^2 represents correlation coefficient).](image.png)
Up-regulation of Id1 in peripheral blood of psoriatic patients

mechanism via the tyrosine kinase signaling pathway. However, this speculation should be experimentally proven in the future study.

It has been shown using a T-cell line model that Id1 expression stimulates baseline levels of NF-κB activity and further enhances NF-κB activation upon T-cell receptor signaling, and that Id1-potentiated activation of NF-κB leads to overproduction of cytokines such as TNF-α and interferon gamma (IFN-γ) in a T-cell line as well as in thymocytes (Yang et al., 2006). Since it has been well documented that an increase in cytokine levels produced by Th1 cells, including TNF-α and IFN-γ, is observed in lesional T lymphocytes and circulating T lymphocytes of patients with psoriasis (Ettehadi et al., 1994; Bonifati et al., 1994; Prinz et al., 1994; Vollmer et al., 1994; Bata-Csorgo et al., 1995a,b; Szabo et al., 1998; Austin et al., 1999; Friedrich et al., 2000), the overexpression of these cytokines may occur as a result of Id1-potentiated activation of NF-κB. Interestingly, a recent genome-wide scan further emphasized the role of the NF-κB pathway in psoriasis (Nair et al., 2009). The molecular connections between Id1, NF-κB and cytokine production in psoriatic PBMCs will therefore be of great interest to investigate in the near future.

Since Id1 expression has been primarily found in lymphocytes in a proliferative state (Rivera and Murre, 2001), “psoriatic patients’ PBMCs having greater proliferative potential” was our other hypothesis in the present investigation. Based on the PHA stimulation assay, the two groups showed no difference in cell proliferation as reflected by SI. There was only one patient with psoriasis whose PBMCs did not respond well to PHA. This might have been due to certain factors such as elderly age and disease associated with a defect in cell-mediated immunity. In addition, we found no correlation between PASI score and SI, implying that SI can not be used as an indicator of disease severity with regard to psoriasis.

Because psoriasis is a chronic and recurrent inflammatory skin disease, patients with psoriasis are likely to have a rise in leukocytes, primarily neutrophils (Rocha-Pereira et al., 2004). However, our recent investigation revealed an increase in lymphocytes in psoriatic patients as compared to those of healthy controls (Ketboonlue, 2007), which was in accordance with previous reports by others (Rocha-Pereira et al., 2004; Böhm, 2006), thereby supporting the notion of PBMCs as attention-grabbing targets in the present study.

In conclusion, our semi-quantitative RT-PCR results in the present study demonstrate over-expression of Id1 mRNA transcripts in PBMCs of patients with psoriasis as compared to those of healthy controls, whereas there is no difference in immune response between the two groups as determined using the PHA non-specific cell-mediated immunity stimulation test. This finding may provide a novel insight into the pathogenesis of this disease as well as indicating a potential therapeutic target. Nevertheless, further studies should be conducted to investigate the regulation of Id1 in immunopathogenesis and its therapeutic potential in psoriasis, e.g., is the therapeutic effect of systematically administered anti-psoriatic drugs linked to suppression of Id1? It would also be of great interest to define target genes and binding partners for Id1 in immune cells during the pathogenesis of this disease.

ACKNOWLEDGMENTS

Research supported by a TRF-CHE research grant for new scholar (#MRG4880147). We gratefully acknowledge the active participation of healthy controls and patients with psoriasis. Also, we would like to thank Ms. Phantipa Protjaroen for her excellent technical assistance.
REFERENCES


Up-regulation of Id1 in peripheral blood of psoriatic patients


